Get the Stockscreener App
3.21
4.46%
-0.15
Pre-market:
3.25
0.04
+1.25%
Rocket Pharmaceuticals Inc stock is traded at $3.21, with a volume of 3.38M.
It is down -4.46% in the last 24 hours and up +15.88% over the past month.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
See More
Previous Close:
$3.36
Open:
$3.32
24h Volume:
3.38M
Relative Volume:
0.69
Market Cap:
$342.78M
Revenue:
-
Net Income/Loss:
$-258.08M
P/E Ratio:
-1.1673
EPS:
-2.75
Net Cash Flow:
$-202.32M
1W Performance:
-3.89%
1M Performance:
+15.88%
6M Performance:
-70.03%
1Y Performance:
-87.18%
1-Day Range:
$3.16
$3.33
1-Week Range:
$3.03
$3.42
52-Week Range:
$2.19
$26.98
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals Inc
Sector
Industry
Phone
646-440-9100
Address
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
3.21 | 362.00M | 0 | -258.08M | -202.32M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-30-25 | Downgrade | Evercore ISI | Outperform → In-line |
| May-28-25 | Downgrade | Goldman | Neutral → Sell |
| May-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-28-25 | Downgrade | Jefferies | Buy → Hold |
| May-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-28-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-27-25 | Downgrade | Needham | Buy → Hold |
| May-27-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Dec-30-24 | Initiated | Wedbush | Outperform |
| Dec-18-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-01-23 | Initiated | Morgan Stanley | Overweight |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Nov-01-22 | Initiated | BTIG Research | Buy |
| Jul-08-22 | Initiated | Raymond James | Outperform |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Feb-18-21 | Initiated | Needham | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-08-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-02-20 | Initiated | JP Morgan | Overweight |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| Nov-06-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-26-19 | Initiated | Piper Jaffray | Overweight |
| Apr-23-19 | Initiated | Robert W. Baird | Outperform |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Feb-05-19 | Initiated | Oppenheimer | Outperform |
| Sep-13-18 | Initiated | Ladenburg Thalmann | Buy |
| Jul-10-18 | Initiated | William Blair | Outperform |
View All
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
Rocket Pharmaceuticals Inc. Equity Warrant Stock Analysis and ForecastFree Predictions - PrintWeekIndia
Rocket Pharmaceuticals Inc. Stock Analysis and ForecastHigh-octane financial growth - PrintWeekIndia
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - TradingView
Levi & Korsinsky Urges Rocket Pharmaceuticals, Inc. (RCKT) Shareholders to Act Before Lead Plaintiff Deadline August 11, 2025 - Barchart.com
Investor Alert: Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Trial Safety Concerns - TradingView
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
What analysts say about Rocket Pharmaceuticals Inc. Equity Warrant stockAccelerated investment success - PrintWeekIndia
Rocket Pharmaceuticals to cut 30% of workforce - NJBIZ
Rocket Pharma falls on delay of certain drug development programs - TradingView
Rocket Pharmaceuticals (RCKT) Restructures, Cuts Workforce by 30% - GuruFocus
Rocket Pharmaceuticals cuts headcount, realigns pipeline - Seeking Alpha
The Fragile Equilibrium: Assessing Rocket Pharmaceuticals Amid Securities Litigation and Governance Concerns - AInvest
RCKT LAWSUIT ALERT: The Gross Law Firm Notifies Rocket Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - PR Newswire
Rocket Pharmaceuticals (RCKT) Restructures for Strategic Focus a - GuruFocus
Rocket Pharmaceuticals Announces Strategic Reorganization - TipRanks
Rocket Pharmaceuticals cuts workforce by 30% to focus on heart therapies - Investing.com Australia
Rocket Pharmaceuticals Announces Strategic Corporate Reorganizat - GuruFocus
Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs - Business Wire
FDA Clinical Hold on RP-A501 Trial Triggers Rocket - GlobeNewswire
Rocket Pharmaceuticals Announces Strategic Reorganization Plan - TipRanks
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Join Class Action Before August 11, 2025Contact Levi & Korsinsky - Barchart.com
Investor Alert: Securities Class Action Filed Against Rocket Pharmaceuticals (RCKT) - TradingView
RCKT Class Action Reminder: Robbins LLP Reminds Rocket Pharmaceuticals, Inc. Investors of the Class Action LawsuitContact us for more information - PR Newswire
RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - PR Newswire
RCKT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In RCKT To Contact Him Directly To Discuss Their Options - PR Newswire
Signaturefd LLC Increases Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - StreetInsider
Levi & Korsinsky Notifies Rocket Pharmaceuticals, Inc. (RCKT) Shareholders of Class Action Lawsuit and August 11, 2025 Deadline - Barchart.com
Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop - TradingView
ROSEN, A TOP RANKED LAW FIRM, Encourages Rocket - GlobeNewswire
ROSEN, A TOP RANKED LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT - GlobeNewswire Inc.
FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class ActionHagens Berman - TradingView
Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
What drives Rocket Pharmaceuticals Inc. Equity Warrant stock priceTremendous growth potential - jammulinksnews.com
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Join - GlobeNewswire
ROCKET PHARMACEUTICALS, INC. (NASDAQ: RCKT) SHAREHOLDER - GlobeNewswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Rocket Pharmaceuticals Inc (RCKT) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT)August 11, 2025 Deadline to JoinContact The Gross Law Firm - PR Newswire
INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
Is Rocket Pharmaceuticals Inc. a good long term investmentAccelerated capital growth - jammulinksnews.com
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky to Join Class Action Before August 11, 2025 - ACCESS Newswire
2025-07-20 | Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky to Join Class Action Before August 11, 2025 | NDAQ:RCKT | Press Release - Stockhouse
What analysts say about Rocket Pharmaceuticals Inc. stockRapid-fire capital growth - jammulinksnews.com
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire
2025-07-20 | RCKT LAWSUIT ALERT: Levi & Korsinsky Notifies Rocket Pharmaceuticals, Inc. InvestorsLead Plaintiff Deadline August 11, 2025 | NDAQ:RCKT | Press Release - Stockhouse
2025-07-19 | RCKT ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Rocket Pharmaceuticals, Inc.August 11, 2025 Deadline | NDAQ:RCKT | Press Release - Stockhouse
What drives Rocket Pharmaceuticals Inc. stock priceHigh-profit trading signals - Jammu Links News
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Rocket - GlobeNewswire
Is Rocket Pharmaceuticals Inc. Equity Warrant a good long term investmentUnrivaled growth potential - jammulinksnews.com
2025-07-18 | Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Join Class Action Before August 11, 2025Contact Levi & Korsinsky | NDAQ:RCKT | Press Release - Stockhouse
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.32%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):